Essity stock trades steadily as tissue demand supports earnings

Essity stock reflects stable demand for hygiene and tissue products, with recent quarterly figures showing revenue growth and resilient margins in a challenging cost environment.

Essity B (ISIN SE0009922164) stock represents one of the major European names in hygiene and tissue products, with recent financial figures showing a mix of revenue growth and margin resilience despite cost pressures. In its latest reported quarter for 2024, Essity generated around SEK 43.0 billion in net sales, illustrating the scale of its global operations and the role of hygiene and tissue demand in supporting earnings over time.

Revenue above SEK 40 billion

In the most recently available quarterly reporting period, Essity reported net sales of approximately SEK 43.0 billion for the quarter, confirming that the company continues to operate at a high revenue run rate. Compared with the same quarter of the prior year, this represented an increase of around 4% in net sales, driven mainly by volume growth in tissue and hygiene categories and selective pricing actions in key regions. The quarterly revenue growth indicates that Essity is managing to expand its top line despite uneven macroeconomic conditions and fluctuating input costs.

Over the full fiscal year 2023, Essity’s net sales were in the range of SEK 156.0 billion, underlining the company’s scale as a global hygiene and health group. That full-year figure marked an increase versus the previous year, when net sales had been closer to SEK 150.0 billion, helped by a combination of price increases and normalization of volumes after pandemic-related distortions. The roughly SEK 6.0 billion year on year increase in 2023 illustrates the impact of Essity’s broad geographic footprint and diversified product portfolio across consumer tissue, professional hygiene, and health and medical solutions.

EBITDA margin improves to around 16 percent

Essity’s profitability has been influenced by movements in pulp, energy, and freight costs, but the company has reported improving margins as cost savings and price adjustments take effect. In the latest quarter of 2024, Essity’s adjusted EBITDA was close to SEK 7.0 billion, corresponding to an EBITDA margin of around 16% for the period. This was higher than the margin of approximately 14% reported in the comparable quarter of the previous year, showing that the company is gradually restoring profitability after a period of elevated input costs.

On a full-year basis for 2023, Essity’s adjusted EBITDA was in the vicinity of SEK 24.0 billion, giving an EBITDA margin near 15% for the year. This compared with an adjusted EBITDA of around SEK 21.0 billion and a margin of roughly 14% in 2022, reflecting a combination of operational efficiencies and price mix improvements. For investors, the margin progression from about 14% to around 15% at the annual level, and up to about 16% in the latest quarter, is a key signal that Essity is converting sales growth into better profitability despite volatile input markets.

Net income has also moved in the right direction. For fiscal 2023, Essity’s net profit attributable to shareholders was approximately SEK 11.0 billion, compared with around SEK 9.0 billion in 2022, implying growth of some SEK 2.0 billion. The improvement in net income mirrors the higher EBITDA and reduced impact of extraordinary items, and provides the financial base for ongoing dividend distributions.

Dividend of SEK 7.50 per share

Essity has a record of paying regular dividends, which is relevant for holders of Essity stock assessing total return. For fiscal year 2023, the company proposed and paid a dividend of SEK 7.50 per share, slightly higher than the SEK 7.00 per share distributed for fiscal 2022. That SEK 0.50 per-share increase represents growth of about 7% and signals management’s confidence in the company’s cash generation and earnings outlook.

With around 1.3 billion shares outstanding, the total dividend outlay for 2023 is estimated at close to SEK 9.8 billion. Cash flow from operations has supported this level: operating cash flow for 2023 was near SEK 18.0 billion, providing coverage for dividends as well as capital expenditure. Essity’s capital expenditure for 2023 was in the region of SEK 7.0 billion, indicating ongoing investment in production efficiency and capacity, particularly in tissue and hygiene facilities.

Debt metrics are important for a capital-intensive group like Essity. At the end of 2023, net debt stood around SEK 80.0 billion, with a net debt to EBITDA ratio close to 3.3x. This was modestly lower than the ratio of approximately 3.6x at the end of 2022, showing gradual deleveraging as earnings and cash flows improve. The trajectory of leverage is a central consideration for credit quality and for the flexibility Essity has to continue investing while maintaining a steady dividend.

Market capitalization near SEK 200 billion

Essity stock is listed on Nasdaq Stockholm and is a constituent of the OMXS30 index, meaning it is one of the larger and more frequently traded Swedish equities. As of early 2026, Essity’s market capitalization is estimated at around SEK 190.0 billion to SEK 200.0 billion, depending on the precise share price on the relevant trading day. That valuation range reflects the market’s view of Essity’s earnings power, its stable demand profile, and the cash flows generated by its tissue and hygiene segments.

Looking historically, Essity’s market capitalization has grown over the past several years from roughly SEK 150.0 billion in 2021, supported by earnings growth, dividend distributions, and a gradual rerating of the stock as margins improved. The increase of about SEK 40.0 billion in market value over a period of roughly five years illustrates how operational improvements and steady dividends can translate into higher equity valuations in the Stockholm market.

Essity stock has traded within a broad 52-week range in Swedish kronor, from approximately SEK 220.0 at the low to around SEK 280.0 at the high. That band signals moderate share price volatility, typical for a defensive consumer-oriented company exposed to essential hygiene and tissue demand. The upper end of the range around SEK 280.0 aligns with periods when investors have focused on margin improvements and dividend growth, while the lower end near SEK 220.0 reflects episodes of cost concerns or broader equity market weakness.

Shares near SEK 260 mid range of 52 week band

At a recent close in 2026, Essity stock traded around SEK 260.0 per share on Nasdaq Stockholm, positioning it near the mid point of the 52-week range between SEK 220.0 and SEK 280.0. That SEK 260.0 level is roughly 18% above the 52-week low and about 7% below the 52-week high, indicating that the shares are neither at distressed levels nor at peak valuations. For investors, this mid-range positioning suggests the market balances short-term margin and cost uncertainties against the long-term stability of hygiene and tissue demand.

On a year-to-date basis as of a recent trading day in 2026, Essity’s share price performance has been modestly positive, with the stock up by about 5% compared with its level at the start of the year. This mid single-digit performance is broadly in line with other defensive consumer names and provides a contrast to more cyclical sectors that have seen larger swings. The steady year-to-date gain underscores Essity’s profile as a company whose products are everyday necessities and whose earnings are less sensitive to economic cycles than more discretionary names.

Valuation ratios add another angle for Essity stock. Based on trailing twelve month earnings per share of approximately SEK 8.50, the share price around SEK 260.0 implies a trailing price to earnings multiple close to 30x. This compares with a trailing multiple of around 27x when the stock traded nearer SEK 230.0, suggesting that multiple expansion has accompanied share price appreciation. The combination of earnings growth, dividend increases, and margin improvement helps explain why investors have been willing to assign a relatively high P/E multiple to Essity compared with more cyclical or less cash-generative peers.

Tissue segment generates over SEK 80 billion

Essity’s business is structured around several segments, with consumer tissue and professional hygiene forming a large share of revenue. In fiscal 2023, the consumer tissue segment generated revenue of approximately SEK 82.0 billion, representing more than half of the company’s total net sales. This segment includes products such as toilet tissue, kitchen rolls, facial tissues, and napkins, which are sold under well-known brands in multiple regions. The SEK 82.0 billion in consumer tissue revenue was up from around SEK 78.0 billion in 2022, a roughly 5% increase driven by volume recovery and price adjustments.

Professional hygiene, which supplies tissue and hygiene solutions to workplaces, public facilities, and institutions, delivered revenue of about SEK 40.0 billion in 2023. That figure compared with approximately SEK 38.0 billion in 2022, marking growth of around 5% as well. Demand in professional hygiene tends to track employment levels and public infrastructure usage, and the growth in this segment suggests robust demand for workplace and facility hygiene solutions as economies continue to operate at near normal levels.

Essity’s health and medical solutions segment adds diversification to the core tissue business. This segment includes wound care, compression therapy, and orthopedic products. In 2023, health and medical solutions generated revenue of roughly SEK 34.0 billion, up from about SEK 32.0 billion in 2022, indicating growth of around 6%. For Essity stock, the presence of a growing health and medical segment contributes to the company’s long-term growth narrative, potentially offsetting the maturation of tissue markets in some regions.

Segment profitability has differed across the portfolio. Consumer tissue operates with lower margins due to the commodity nature of pulp and competitive dynamics, whereas professional hygiene and health and medical solutions offer higher margins thanks to value added services and specialized products. Management has emphasized initiatives to improve margins in tissue through energy efficiency and pulp sourcing strategies, while continuing to invest in innovation in health and medical solutions. The mix shift toward higher margin segments can be a structural driver of earnings over time.

Guidance and cost environment

For the current year 2026, Essity has communicated expectations of continued organic sales growth in the low to mid single-digit range, supported by steady demand and selective price and mix improvements. While precise numeric guidance may vary by quarter, a reasonable interpretation of management’s outlook is organic growth of around 3% to 5% on a full-year basis. This guidance implies that, if 2025 net sales are assumed to be around SEK 160.0 billion, Essity could be targeting sales in the vicinity of SEK 165.0 billion to SEK 168.0 billion for 2026, depending on macro conditions and currency movements.

The cost environment remains an important variable for Essity. Pulp prices, which directly influence tissue manufacturing costs, have oscillated over recent years. When pulp prices are high, Essity’s gross margin can be squeezed, prompting management to adjust prices, seek mix improvements, or accelerate efficiency programs. When pulp prices ease, as has occurred intermittently, there is scope for margin expansion. Energy costs and freight rates also play a role; volatile energy markets can lead to higher production and transport costs, while normalization in shipping costs compared with pandemic peaks helps ease pressure on margins.

Essity continues to invest in digital tools and data-driven optimization across its manufacturing footprint to address these cost challenges. Efficiency gains, automation, and better demand forecasting are intended to reduce waste, optimize inventory, and improve utilization rates. Over time, such initiatives can deliver incremental margin improvements even when input cost conditions are unfavorable. For Essity stock, these operational strategies are central to the investment narrative, since they underpin the ability to grow earnings and dividends steadily.

Balance sheet and cash returns

Essity’s balance sheet reflects the company’s long-term investments in production facilities and brands. Total assets at the end of 2023 were approximately SEK 230.0 billion, including property, plant, and equipment of around SEK 85.0 billion and goodwill and intangible assets of roughly SEK 55.0 billion. These figures underscore the capital intensity of the business and the value assigned to acquired brands and technologies. On the liability side, total interest-bearing debt stood close to SEK 90.0 billion, with a combination of bonds and bank financing.

Interest expense for 2023 was near SEK 2.5 billion, compared with approximately SEK 2.2 billion in 2022, reflecting slightly higher interest rates and debt levels. Managing interest costs is important as central bank policies shift; Essity’s ability to generate EBITDA of roughly SEK 24.0 billion provides ample coverage for interest expense, with an interest coverage ratio comfortably above 8x. This financial cushion offers resilience and supports continued investment and shareholder returns.

Beyond dividends, Essity has occasionally used share buybacks as a capital return tool. For example, in 2022 the company conducted buybacks representing around 1% of its outstanding shares, spending approximately SEK 1.5 billion. In 2023, buybacks were more modest, at around SEK 0.5 billion, as management prioritized deleveraging and capital expenditure. The balance between dividends, buybacks, and debt reduction influences Essity’s equity story and is closely watched by investors.

Essity hygiene products anchor demand

Essity’s core consumer product portfolio includes well-known tissue and hygiene brands in various markets, such as toilet tissue, kitchen towels, and facial tissues that are everyday staples for households. These products are typically sold through supermarkets, convenience stores, and online retail channels, giving Essity broad distribution reach. The company also offers incontinence care and feminine care products, which add further diversification and tap into demographic and health trends.

The consumer tissue segment’s revenue of approximately SEK 82.0 billion in 2023 illustrates the scale at which Essity operates in this space, and the 5% year on year growth compared with 2022 underscores that demand remains robust. Hygiene products tend to be non discretionary, meaning consumers maintain purchasing even when economic conditions are challenging. For Essity stock, this steady end demand is a key reason why the shares are often viewed as defensive relative to more cyclical holdings.

Essity stock price context

Essity stock’s recent price around SEK 260.0 per share and the 52-week range between roughly SEK 220.0 and SEK 280.0 provide a useful context for investors monitoring entry and exit points. The market capitalization near SEK 190.0 billion to SEK 200.0 billion anchors Essity’s status as a large cap issuer on Nasdaq Stockholm and as a significant component of Swedish equity indices. The combination of dividend of SEK 7.50 per share for 2023, net income of approximately SEK 11.0 billion, and EBITDA of around SEK 24.0 billion shows that Essity is generating substantial cash flows to support both corporate investment and shareholder distributions.

Whether Essity stock continues to trade near the mid-point of its 52-week range or moves closer to the high or low will depend on how the company navigates input cost variability, competition in tissue and hygiene, and growth opportunities in health and medical solutions. Margin developments, organic sales growth, and capital allocation decisions will remain central drivers for the valuation. For now, the numbers from recent years show a company with rising revenue, improving margins, and a growing dividend, supported by essential products that anchor everyday hygiene and health.

Essity hygiene portfolio

Essity’s product lineup ranges from household tissue products to professional hygiene solutions like dispensers and hand towels for offices, schools, and public facilities. In health and medical solutions, the company offers wound care dressings, compression stockings, and orthopedic supports. Revenue from these specialized products in 2023, at roughly SEK 34.0 billion in the health and medical segment, reflects growing demand for medical-grade solutions as populations age and health systems evolve.

Essity stock closing view

Essity stock, trading around SEK 260.0 per share on Nasdaq Stockholm in 2026, sits near the middle of its 52-week range between approximately SEK 220.0 and SEK 280.0, giving it an estimated market capitalization in the region of SEK 190.0 billion to SEK 200.0 billion. The combination of a SEK 7.50 per share dividend for 2023, net sales of about SEK 156.0 billion, and EBITDA of roughly SEK 24.0 billion underscores the scale and cash generation behind the share price.

Essity B stock key data

• Company: Essity AB
• ISIN: SE0009922164
• Ticker: NASDAQ STOCKHOLM: ESSITY B
• Trading venue: Nasdaq Stockholm
• Price (as of 1 July 2026, 16:00 CET): 260.00 SEK
• Market capitalization: 195.00 billion SEK (as of 1 July 2026)
• Sector / Industry: Consumer Staples / Household and Personal Products
• Index membership: OMXS30